[1] |
Peppas G,Alexiou VG,Mourtzoukou E, et al.Epidemiology of constipation in Europe and Oceania:a systematic review.BMC Gastroenterol, 2008, 8: 5.
|
[2] |
Gray JR.What is chronic constipation? Definition and diagnosis.Can J Gastroenterol, 2011, 25: 7-10.
|
[3] |
O’Donnell L,Virjee J,Heaton KW.Detection of pseudodiarrhea by simple clinical assessment of intestinal transit rate.Br Med J, 1990, 300: 439-440.
|
[4] |
Longstreth GF,Thompson WG,Chey WD, et al.Functional bowel disorders.Gastroenterology, 2006, 130: 1480-1491.
|
[5] |
Belsey J,Greenfield S,Candy D, et al.Systematic review:impact of constipation on quality of life in adults and children.Aliment Pharmacol Ther, 2010, 31: 938-949.
|
[6] |
Paré P,Bridges R,Champion MC, et al.Recommendations on chronic constipation(including constipation associated with irritable bowel syndrome)treatment.Can J Gastroenterol, 2007, 21: 3-22.
|
[7] |
Gonlachanvit S,Patcharatrakul T. Causes of idiopathic constipation in Thai patients:associations between the causes and constipation symptoms as defined in the Rome II criteria.J Med Assoc Thai, 2004, 87(2): 22-28.
|
[8] |
Lundin E,Karlbom U,Westlin JE, et al.Scintigraphic assessment of slow transit constipation with special reference to right-or leftsided colonic delay.Colorectal Dis, 2004, 6: 499-505.
|
[9] |
Rao SS,Sadeghi P,Batterson K, et al.Altered periodic rectal motor activity:a mechanism for slow transit constipation.Neurogastroenterol Motil, 2001, 13: 591-598.
|
[10] |
Penning C,Steens J,Schaar PJ, et al.Motor and sensory function of the rectum in different subtypes of constipation.Scand J Gastroenterol, 2001, 36: 32-38.
|
[11] |
Leung L,Riutta T,Kotecha J, et al.Chronic constipation:an evidence-based review.J Am Board Fam Med, 1999, 24: 436-451.
|
[12] |
World Gastroenterology Organisation.WGO practice guidelines:constipation, 2007.
|
[13] |
Locke GR,Pemberton JH,Phillips SF.AGA technical review on constipation.American Gastroenterological Association.Gastroenterology, 2000, 119: 1766-1778.
|
[14] |
Ramkumar D,Rao SS.Efficacy and safety of traditional medical therapies for chronic constipation:systematic review.Am J Gastroenterol, 2005, 100: 936-971.
|
[15] |
Camilleri M,Kerstens R,Rykx A, et al.A placebo-controlled trial of prucalopride for severe chronic constipation.N Engl J Med, 2008, 358: 2344-2354.
|
[16] |
Tack J,van Outryve M,Beyens G, et al.Prucalopride(Resolor)in the treatment of severe chronic constipation in patients dissatisfied with laxatives.Gut, 2009, 58: 357-365.
|
[17] |
Quigley EM,Vandeplassche L,Kerstens R, et al.Clinical trial:the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebocontrolled study.Aliment Pharmacol Ther, 2009, 29: 315-328.
|
[18] |
Quigley EM.Prucalopride:safety, efficacy and potential applications.Am J Gastroenterol, 2005, 100: 936-971.
|
[19] |
Ke M,Zou D,Yuan Y, et al.Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region:a randomized, double-blind, placebo-controlled study.Neurogastroenterol Motil, 2012, 24: 999-541.
|
[20] |
Potet F,Bouyssou T,Escande D, et al.Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+)channel.J Pharmacol Exp Ther, 2001, 299: 1007-1012.
|
[21] |
Ford AC,Suares NC.Effect of laxatives and pharmacological therapies in chronic idiopathic constipation:systematic review and meta-analysis.Gut, 2011, 60: 209-218.
|
[22] |
Liu LW.Chronic constipation:current treatment options.Can J Gastroenterol, 2011, 25: 22-28.
|
[23] |
Johanson JF,Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation:a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety.Aliment Pharmacol Ther, 2007, 25: 1351-1361.
|
[24] |
Johanson JF,Morton D,Geenen J, et al.Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation.Am J Gastroenterol, 2008, 103: 170-177.
|
[25] |
Barish CF,Drossman D,Johanson JF, et al.Efficacy and safety of lubiprostone in patients with chronic constipation.Dig Dis Sci, 2010, 55: 1090-1097.
|
[26] |
Chey WD,Lembo AJ,Lavins BJ, et al.Linaclotide for irritable bowel syndrome with constipation:a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.Am J Gastroenterol, 2012, 107: 1702-1712.
|
[27] |
Food and Drug Administration.Guidance for industry:irritable bowel syndrome-clinical evaluation of drugs for treatment, 2012.
|
[28] |
Rao S,Lembo AJ,Shiff SJ, et al.A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.Am J Gastroenterol, 2012, 107: 1714-1124.
|
[29] |
Lembo AJ,Schneier HA,Shiff SJ, et al.Two randomized trials of linaclotide for chronic constipation.N Engl J Med, 2011, 365: 527-536.
|